Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
Incyte to Present Latest Dermatology Portfolio Data at 2025 AAD Annual Meeting
  • Press Releases

Incyte to Present Latest Dermatology Portfolio Data at 2025 AAD Annual Meeting

  • The Pharma Data
  • March 1, 2025

Incyte (Nasdaq: INCY) has announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 7–11, 2025, in Orlando, where the company will present multiple…

Read MoreIncyte to Present Latest Dermatology Portfolio Data at 2025 AAD Annual Meeting
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day
  • News

Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

  • The Pharma Data
  • March 1, 2025

Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day Arrowhead Pharmaceuticals Expands “We’ll Get There Soon” Campaign with New Resources for Familial Chylomicronemia Syndrome on Rare Disease Day Arrowhead…

Read MoreArrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day
  • Press Releases

Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program

  • The Pharma Data
  • March 1, 2025

Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has officially opened applications…

Read MoreSarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program
CHMP Recommends EU Approval of ENHERTU® for HER2 LowUltralow Metastatic Breast Cancer
  • Regulatory

CHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer

  • The Pharma Data
  • March 1, 2025

CHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have achieved a significant milestone with the recommendation for approval…

Read MoreCHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases
  • Research

Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases

  • The Pharma Data
  • March 1, 2025

Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin…

Read MoreSeismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases
  • Press Releases

BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies

  • The Pharma Data
  • March 1, 2025

BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies targeting RAS…

Read MoreBridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies
  • Research

Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema

  • The Pharma Data
  • March 1, 2025

Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases,…

Read MoreAstria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema
Vertex Gains CHMP Nod for KAFTRIO® Label Expansion
  • News

Vertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations

  • The Pharma Data
  • March 1, 2025

Vertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations Vertex Pharmaceuticals (Nasdaq: VRTX) has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read MoreVertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations
Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion
  • Press Releases

Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion

  • The Pharma Data
  • March 1, 2025

Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion Predictmedix AI Expands into US Market with Launch of Advanced AI Health Stations Predictmedix AI Inc. (CSE: PMED) (OTC:…

Read MorePredictmedix AI Unveils Advanced AI Health Stations for US Market Expansion
SINOVAC Appoints New Board Following Privy Council Ruling
  • Press Releases

SINOVAC Appoints New Board Following Privy Council Ruling

  • The Pharma Data
  • March 1, 2025

SINOVAC Announces New Board Following Privy Council Judgment and Outlines Next Steps Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, has announced significant developments…

Read MoreSINOVAC Appoints New Board Following Privy Council Ruling
Identiv and Novanta Form Strategic Partnership to Accelerate RFID Adoption in Healthcare OEMs
  • Business

Identiv and Novanta Form Strategic Partnership to Accelerate RFID Adoption in Healthcare OEMs

  • The Pharma Data
  • February 28, 2025

Identiv and Novanta Forge Strategic Partnership to Accelerate Adoption of RFID Solutions in Healthcare OEMs Novanta Inc., a leading global technology supplier serving the medical device and life sciences markets,…

Read MoreIdentiv and Novanta Form Strategic Partnership to Accelerate RFID Adoption in Healthcare OEMs
Immune-Onc Doses First Patient in IO-108 Phase 1b2 Liver Cancer Trial with Roche
  • Research

Immune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Trial with Roche

  • The Pharma Data
  • February 28, 2025

Immune-Onc Therapeutics Doses First Patient with IO-108 in Global Phase 1b/2 Liver Cancer Study in Collaboration with Roche Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company focused on developing…

Read MoreImmune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Trial with Roche
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • UCB Expands Immunology Portfolio with Acquisition of Candid Therapeutics, Advancing Novel T-Cell Engager Strategy
  • J&J Statement on FDA Approval of STELARA® for Pediatric Crohn’s Disease
  • Incyte Wins FDA Approval for Jakafi XR™ Extended-Release Tablets Across Multiple Hematologic Indications
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.